Results 101 to 110 of about 2,377,300 (402)

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

Molecular Oncology, EarlyView.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes   +17 more
wiley   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

[Nintedanib for the treatment of idiopathic pulmonary fibrosis in Italy]

Farmeconomia: Health Economics and Therapeutic Pathways, 2017
To date, there are few therapeutic answers for Idiopathic pulmonary fibrosis (IPF) and only two pharmacological treatments have a marketing authorization for this disease.
Andrea Belisari, Daria Bettoni, Paolo Angelo Cortesi, Lucia Sara D'Angiolella, Lorenzo Giovanni Mantovani, Gerardo Miceli Sopo, Marino Nonis   +6 more
doaj   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

Molecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin   +10 more
wiley   +1 more source

Three‐year cost utility analysis of mini versus standard slings: A trial based economic evaluation

BJUI Compass
Objective To report on the cost‐effectiveness of adjustable anchored single‐incision mini‐slings (mini‐slings) compared with tension‐free standard mid‐urethral slings (standard slings) in the surgical management of female stress urinary incontinence (SUI)
Mary Kilonzo, Dwayne Boyers, David Cooper, Tracey Davidson, Kiron Bhal, James N'Dow, Graeme MacLennan, John Norrie, Mohamed Abdel‐Fattah   +8 more
doaj   +1 more source

Pharmaco-economics analysis, as a strategy on facilitating choices between health and non-health programs in the establishment of the national health care system

Alexandria Journal of Medicine, 2014
Due to the significant boost in community expenditure with health topics, mainly regarding drugs, numerous countries, have already put into operation, or are in the process of arguing the adoption of actions to guarantee the excellence of health care ...
Adanela Musaraj, Arta Musaraj, Aida Dervishi   +2 more
doaj   +1 more source

Evaluation of physiotherapy using cost-utility analysis

Australian Journal of Physiotherapy, 1993
Limits on health care resources mean that resource allocation decisions should be guided by considerations of cost in relation to benefits. A method of economic evaluation, (cost-utility analysis) was used to evaluate the costs and benefits of a physiotherapy outpatient department.
openaire   +2 more sources

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

COST-EFFECTIVENESS AND COST-UTILITY OF GENOTHERAPEUTIC DRUG NEOVASCULGEN IN TREATMENT OF CHRONIC LOWER LIMB ISCHEMIA

Медицинский совет, 2017
Pl-VEGF165 (Neovasculgen) is a new genotherapeutic drug for treatment of chronic lower limb ischemia.  It is registered in Russia and underwent effectiveness assessment in clinical trial.
S. L. Plavinsky, P. I. Shabalkin
doaj   +1 more source

Cost-effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage IIIC and IV epithelial ovarian cancer. [PDF]

, 2016
ObjectivesTo examine the cost-effectiveness of primary debulking surgery (PDS) when compared to neoadjuvant chemotherapy (NACT) in the management of epithelial ovarian cancer (EOC) using Surveillance, Epidemiology, and End Results data linked to Medicare
Chang, Jenny, Forde, Gareth K, Ziogas, Argyrios   +2 more
core   +1 more source